TNF Pharmaceuticals Financials
This page shows TNF Pharmaceuticals (TNFA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
TNF Pharmaceuticals remains a financing-dependent development company, with capital raises funding research while cash reserves stay thin.
FY2025’s smaller net loss did not ease funding needs: operating cash flow was-$9.1M , essentially unchanged from FY2024’s-$9.0M . The company still relied on$18.3M of financing cash flow, implying the earnings improvement was driven more by non-cash or non-operating items than by lower cash use.
Short-term liquidity looked better in FY2025, with the current ratio at 3.0x versus 1.4x in FY2024. But the drop in debt-to-equity to 0.8x from 1.2x appears to reflect balance-sheet replenishment from external funding rather than self-funded strengthening.
Reported capital is less liquid than book equity suggests: goodwill was
Financial Health Signals
TNF Pharmaceuticals does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
TNF Pharmaceuticals passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
TNF Pharmaceuticals reported a net loss of $11.6M while operations used $9.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
TNF Pharmaceuticals reported -$11.6M in net income in fiscal year 2025. This represents an increase of 50.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
TNF Pharmaceuticals recorded an outflow of $10.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
TNF Pharmaceuticals held $987K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
TNF Pharmaceuticals's ROE was -53.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 185.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
TNF Pharmaceuticals invested $3.5M in research and development in fiscal year 2025. This represents an increase of 0.9% from the prior year.
TNF Pharmaceuticals invested $1.8M in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
TNFA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.6M-5.3% | $1.7M-50.4% | $3.4M+13.3% | $3.0M+40.0% | $2.1M-52.2% | $4.4M+23.7% | $3.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.1M-28.6% | $1.5M-36.1% | $2.4M+1635.2% | $139K+20.1% | $115K+61.6% | $71K-96.3% | $1.9M |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $479K+276.1% | $127K-86.6% | $949K-49.5% | $1.9M+61.3% | $1.2M-64.2% | $3.3M+95.4% | $1.7M |
| R&D Expenses | N/A | $3.5M+0.9% | $3.4M-56.3% | $7.9M-13.2% | $9.1M+34.4% | $6.7M+173.4% | $2.5M+791.3% | $277K-74.0% | $1.1M-15.6% | $1.3M+6.0% | $1.2M-15.5% | $1.4M+53.5% | $916K-9.0% | $1.0M |
| SG&A Expenses | N/A | $3.7M-10.2% | $4.2M-23.5% | $5.4M-1.4% | $5.5M-14.0% | $6.4M+117.9% | $2.9M-12.6% | $3.4M-40.5% | $5.7M+38.8% | $4.1M+35.7% | $3.0M-25.3% | $4.0M+6.5% | $3.8M+245.3% | $1.1M |
| Operating Income | N/A | -$9.8M+3.2% | -$10.2M+40.6% | -$17.1M-12.0% | -$15.3M+47.0% | -$28.8M | N/A | -$3.5M+65.5% | -$10.1M-52.1% | -$6.6M-98.7% | -$3.3M+65.6% | -$9.7M-202.2% | -$3.2M-77.0% | -$1.8M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$269K | N/A | N/A |
| Net Income | N/A | -$11.6M+50.2% | -$23.4M-484.0% | -$4.0M+73.7% | -$15.2M+49.2% | -$29.9M | N/A | -$3.9M+64.2% | -$10.8M-47.3% | -$7.4M-123.0% | -$3.3M+64.5% | -$9.3M-196.3% | -$3.1M-105.9% | -$1.5M |
| EPS (Diluted) | — | -$8.66 | -$1080.87 | -$5.33 | -$11.74 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TNFA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $41.2M+92.2% | $21.4M+19.9% | $17.9M+1.8% | $17.5M-29.3% | $24.8M+3566.8% | $677K-93.8% | $10.9M+39.4% | $7.8M-16.4% | $9.3M+83.6% | $5.1M-38.5% | $8.3M-50.3% | $16.7M+174.1% | $6.1M |
| Current Assets | $16.6M+76.2% | $9.4M+61.8% | $5.8M+7.7% | $5.4M-57.4% | $12.7M+8371.7% | $150K-98.6% | $10.3M+54.6% | $6.7M-14.2% | $7.8M+144.0% | $3.2M-50.8% | $6.5M-50.4% | $13.1M+287.6% | $3.4M |
| Cash & Equivalents | $987K+470.0% | $173K-93.5% | $2.7M+257.9% | $749K+34.7% | $556K+274.9% | $148K-71.3% | $517K+184.7% | $182K-58.5% | $438K+503.1% | $73K-81.9% | $402K-11.8% | $456K+339.9% | $104K |
| Inventory | N/A | N/A | N/A | N/A | N/A | $198K-0.6% | $199K-66.0% | $585K-38.2% | $948K-53.5% | $2.0M+80.0% | $1.1M+25.0% | $905K-11.7% | $1.0M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $43K-75.7% | $176K-81.7% | $965K+60.4% | $601K-1.3% | $609K-47.2% | $1.2M+874.9% | $118K |
| Goodwill | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.4M+41.4% | $11.6M+128.6% | $5.1M+78.9% | $2.8M+144.0% | $1.2M-80.4% | $5.9M-55.1% | $13.2M+569.8% | $2.0M+10.6% | $1.8M+5.2% | $1.7M+1.7% | $1.7M-9.5% | $1.8M-5.6% | $2.0M |
| Current Liabilities | $5.5M-17.4% | $6.7M+34.3% | $5.0M+80.1% | $2.8M+166.3% | $1.0M-55.7% | $2.3M+53.5% | $1.5M-22.5% | $2.0M+10.6% | $1.8M+5.2% | $1.7M+1.7% | $1.7M-9.5% | $1.8M+11.9% | $1.6M |
| Total Equity | $21.8M+122.2% | $9.8M-20.9% | $12.4M-15.8% | $14.7M-37.9% | $23.6M+549.8% | -$5.3M-125.3% | -$2.3M-140.0% | $5.8M-22.8% | $7.6M+123.0% | $3.4M-48.7% | $6.6M-55.4% | $14.8M+259.2% | $4.1M |
| Retained Earnings | -$144.1M-11.6% | -$129.1M-26.6% | -$102.0M-8.8% | -$93.8M-19.3% | -$78.6M-61.4% | -$48.7M+59.3% | -$119.6M-3.4% | -$115.7M-10.3% | -$104.8M-7.6% | -$97.5M-3.5% | -$94.2M-11.0% | -$84.9M-3.8% | -$81.7M |
Not reported in any period shown, so not listed: Long-Term Debt.
TNFA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.7M | -$9.1M-1.0% | -$9.0M+30.8% | -$13.0M-5.8% | -$12.3M+37.1% | -$19.5M | N/A | -$3.1M+63.8% | -$8.5M-67.4% | -$5.1M-21.7% | -$4.2M+18.7% | -$5.1M-32.1% | -$3.9M-42.3% | -$2.7M |
| Capital Expenditures | N/A | $1.8M | N/A | N/A | N/A | N/A | N/A | N/A | $68K+25.1% | $55K-55.8% | $123K+9.2% | $113K+352.0% | $25K-79.7% | $123K |
| Free Cash Flow | N/A | -$10.8M | N/A | N/A | N/A | N/A | N/A | N/A | -$8.6M-66.9% | -$5.1M-19.5% | -$4.3M+18.1% | -$5.2M-34.2% | -$3.9M-37.0% | -$2.9M |
| Investing Cash Flow | -$8.0M | -$8.4M-38.1% | -$6.1M-430.6% | $1.8M-73.3% | $6.9M-65.2% | $19.9M | N/A | -$3.9M-995.6% | -$360K+92.8% | -$5.0M-230.5% | $3.8M | N/A | N/A | N/A |
| Financing Cash Flow | N/A | $18.3M+45.6% | $12.6M-3.8% | $13.1M+135.4% | $5.6M+7447.7% | $74K | N/A | $7.0M-23.5% | $9.1M-13.0% | $10.5M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TNFA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 30.4%+22.7pp | 7.6%-20.6pp | 28.3%-35.1pp | 63.4%+8.4pp | 55.0%-18.4pp | 73.5%+26.9pp | 46.5% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -220.2% | -604.0% | -197.2% | -112.4% | -457.8% | -72.4%-21.8pp | -50.6% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -246.6% | -651.4% | -219.6% | -111.6% | -440.3% | -71.0%-28.3pp | -42.7% |
| Return on Equity | -53.4%+185.2pp | -238.6%-206.3pp | -32.3%+71.1pp | -103.4%+23.0pp | -126.4% | N/A | N/A | -186.0%-88.4pp | -97.5%0.0pp | -97.5%+43.5pp | -141.0%-119.8pp | -21.2%+15.8pp | -37.0% |
| Return on Assets | -28.2%+80.8pp | -109.0%-86.7pp | -22.4%+64.3pp | -86.6%+33.8pp | -120.5% | N/A | -35.7%+103.2pp | -139.0%-60.1pp | -78.9%-13.9pp | -65.0%+47.6pp | -112.6%-93.7pp | -18.9%+6.3pp | -25.1% |
| Current Ratio | 3.00+1.6x | 1.40+0.2x | 1.17-0.8x | 1.95-10.2x | 12.18+12.1x | 0.06-6.7x | 6.74+3.4x | 3.38-1.0x | 4.36+2.5x | 1.88-2.0x | 3.88-3.2x | 7.08+5.0x | 2.04 |
| Debt-to-Equity | 0.76-0.4x | 1.19+0.8x | 0.41+0.2x | 0.19+0.1x | 0.05 | N/A | N/A | 0.34+0.1x | 0.24-0.3x | 0.50+0.2x | 0.25+0.1x | 0.12-0.3x | 0.47 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -514.6% | -153.1% | -145.1% | -248.0% | -88.3%-8.6pp | -79.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where TNF Pharmaceuticals Ranks
Frequently Asked Questions
Is TNF Pharmaceuticals profitable?
No, TNF Pharmaceuticals (TNFA) reported a net income of -$11.6M in fiscal year 2025.
What is TNF Pharmaceuticals's return on equity (ROE)?
TNF Pharmaceuticals (TNFA) has a return on equity of -53.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is TNF Pharmaceuticals's free cash flow?
TNF Pharmaceuticals (TNFA) recorded an outflow of $10.8M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TNF Pharmaceuticals's operating cash flow?
TNF Pharmaceuticals (TNFA) recorded an outflow of $9.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are TNF Pharmaceuticals's total assets?
TNF Pharmaceuticals (TNFA) had $41.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are TNF Pharmaceuticals's capital expenditures?
TNF Pharmaceuticals (TNFA) invested $1.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does TNF Pharmaceuticals spend on research and development?
TNF Pharmaceuticals (TNFA) invested $3.5M in research and development during fiscal year 2025.
What is TNF Pharmaceuticals's current ratio?
TNF Pharmaceuticals (TNFA) had a current ratio of 3.00 as of fiscal year 2025, which is generally considered healthy.
What is TNF Pharmaceuticals's debt-to-equity ratio?
TNF Pharmaceuticals (TNFA) had a debt-to-equity ratio of 0.76 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is TNF Pharmaceuticals's return on assets (ROA)?
TNF Pharmaceuticals (TNFA) had a return on assets of -28.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is TNF Pharmaceuticals's cash runway?
Based on fiscal year 2025 data, TNF Pharmaceuticals (TNFA) had $987K in cash against an annual operating cash burn of $9.1M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is TNF Pharmaceuticals's Piotroski F-Score?
TNF Pharmaceuticals (TNFA) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are TNF Pharmaceuticals's earnings high quality?
TNF Pharmaceuticals (TNFA) reported a net loss of $11.6M while operations used $9.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.